7,200 Medtronic PLC $MDT Shares Sold by Jmac Enterprises LLC

Jmac Enterprises LLC cut its position in shares of Medtronic PLC (NYSE:MDT) by 65.5% during the third quarter, Holdings Channel.com reports. The firm owned 3,800 shares of the medical technology company’s stock after selling 7,200 shares during the quarter. Jmac Enterprises LLC’s holdings in Medtronic were worth $328,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Gradient Investments LLC raised its position in shares of Medtronic by 3.9% during the 2nd quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock valued at $38,842,000 after buying an additional 18,509 shares during the period. MassMutual Private Wealth & Trust FSB grew its position in Medtronic by 14.8% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 149,708 shares of the medical technology company’s stock worth $12,918,000 after acquiring an additional 19,315 shares during the period. Congress Asset Management Co. purchased a new position in Medtronic in the third quarter worth approximately $76,201,000. Czech National Bank grew its position in Medtronic by 4.7% in the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock worth $28,589,000 after acquiring an additional 16,292 shares during the period. Finally, Worth Asset Management LLC acquired a new stake in Medtronic during the third quarter worth $1,056,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Marinaro sold 10,420 shares of Medtronic stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the transaction, the executive vice president owned 105,916 shares of the company’s stock, valued at $10,167,936. This represents a 8.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 61,903 shares of company stock worth $5,889,203. Company insiders own 0.27% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported that the SPYRAL AFFIRM real-world study found statistically significant, clinically meaningful blood-pressure reductions six months after treatment with its Symplicity Spyral system. Reductions were seen in office, home, and 24-hour ambulatory readings, without an increase in antihypertensive medications. The findings could strengthen the case for the procedure and support future adoption, though the announcement does not quantify potential sales impact. Article
• Neutral Sentiment: Medtronic and the Michael J. Fox Foundation launched an educational initiative to help people with Parkinson’s and caregivers understand deep brain stimulation (DBS). It may raise awareness of an established treatment, but no new product, clinical result, or revenue outlook was announced. Article
• Neutral Sentiment: The company said it will release fiscal Q2 2027 results on November 24. This is a scheduling announcement, with no new financial guidance or operating results. Article
• Negative Sentiment: A report said ETFs were net sellers of MDT, with $110.6 million in outflows on Friday. This is a short-term flow signal and may not indicate a lasting change in investor views. Article
• Negative Sentiment: An analyst roundup cited a consensus price target of $102.88, below the $105.02 reference price in the supplied market data, suggesting limited upside at that level. Article

Analysts Set New Price Targets

A number of equities research analysts have commented on MDT shares. Barclays upgraded Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Wells Fargo & Company increased their price target on Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a report on Wednesday, September 2nd. Bank of America increased their price target on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Robert W. Baird raised their price objective on Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 2nd. Finally, Stifel Nicolaus boosted their price objective on shares of Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a report on Wednesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.88.

Medtronic Price Performance

Shares of NYSE MDT opened at $105.02 on Thursday. The stock’s 50-day moving average is $92.21 and its two-hundred day moving average is $88.39. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a market cap of $134.34 billion, a price-to-earnings ratio of 25.87, a price-to-earnings-growth ratio of 2.31 and a beta of 0.56.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts forecast that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Medtronic Company Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.